OxVax Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Liquidation

  • Investors
  • 1

OxVax General Information

Description

Developer of an advanced next-generation dendritic cell vaccine intended to provide treatment for solid tumor cancers. The company's technology exploits induced pluripotent stem cells (iPSC) as a novel source of CD141+ dendritic cells (DC), a novel proprietary DC subset whose unique properties make them attractive candidates for cancer immunotherapy, enabling patients to get the treatment for intractable cancers.

Contact Information

Website
www.oxvax.uk
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 264 Banbury Road
  • Oxford OX2 7DY
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 264 Banbury Road
  • Oxford OX2 7DY
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OxVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Bankruptcy: Liquidation 13-Jul-2023 Completed Bankruptcy: Liquidation
4. Secondary Transaction - Private 01-Mar-2022 Completed Clinical Trials - General
3. Angel (individual) 17-Jan-2022 Completed Clinical Trials - General
2. Seed Round 21-Apr-2021 $539K $539K Completed Clinical Trials - General
1. University Spin-Out 01-Feb-2021 Completed Clinical Trials - General
To view OxVax’s complete valuation and funding history, request access »

OxVax Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference
Preference
To view OxVax’s complete cap table history, request access »

OxVax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an advanced next-generation dendritic cell vaccine intended to provide treatment for solid tumor cancers. T
Drug Discovery
Oxford, United Kingdom
4 As of 2023

San Diego, CA
 

Mainz, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OxVax Competitors (4)

One of OxVax’s 4 competitors is Neuvogen, a Venture Capital-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neuvogen Venture Capital-Backed San Diego, CA
BioNTech Formerly VC-backed Mainz, Germany
Northwest Biotherapeutics Corporation Bethesda, MD
Lineage Cell Therapeutics Corporation Carlsbad, CA
To view OxVax’s complete competitors history, request access »

OxVax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OxVax Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
University of Oxford University Minority
To view OxVax’s complete investors history, request access »

Ready to get started?

Request a free trial

OxVax FAQs

  • When was OxVax founded?

    OxVax was founded in 2021.

  • Where is OxVax headquartered?

    OxVax is headquartered in Oxford, United Kingdom.

  • What is the size of OxVax?

    OxVax has 4 total employees.

  • What industry is OxVax in?

    OxVax’s primary industry is Drug Discovery.

  • Is OxVax a private or public company?

    OxVax is a Private company.

  • What is OxVax’s current revenue?

    The current revenue for OxVax is .

  • How much funding has OxVax raised over time?

    OxVax has raised $1.01M.

  • Who are OxVax’s investors?

    University of Oxford has invested in OxVax.

  • Who are OxVax’s competitors?

    Neuvogen, BioNTech, Northwest Biotherapeutics, and Lineage Cell Therapeutics are competitors of OxVax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process